ClinicalTrials.gg
Not yet recruitingNCT06894719Updated Oct 22, 2026

Oral Tranexamic Acid After Total Knee Arthroplasty

A Phase 4 interventional study of tranexamic acid Oral-Short Arm and tranexamic acid Oral-Long Arm in Total Knee Arthroplasty, sponsored by Rush University Medical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Rush University Medical Center · Phase 4, Interventional, and Treatment

How we know

Updated Oct 22, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, double-blind, randomized controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in total knee arthroplasty (TKA). The study will assess pain, function, and range of motion (ROM) over a 2-year period, with key evaluations at 6 weeks and 90 days postoperatively.

Hypothesis:

Patients receiving 1.95g oral TXA for 3 or 7 days post-op will show improved pain, function, and ROM at 6 weeks and 90 days, with similar blood loss and transfusion rates as the control group.

Read the detailed description

OBJECTIVES:

Purpose:

This is a prospective, double-blinded, randomized control study to evaluate the efficacy and role of oral Tranexamic acid in total knee arthroplasty by assessing pain, function, and range of motion over a 2-year follow-up period.

Hypothesis:

We hypothesize that those given 1.95g oral TXA for 3- and 7-days post-op will have improved pain, function, and range of motion assessed at the 6-week follow-up along with improved range of motion (ROM) at the 90-day follow-up. Additionally, we expect both the control group and the experimental group to have similar blood loss and transfusion rates.

BACKGROUND:

As the rates of primary and revision total knee arthroplasty (TKA) continue to rise in the United States2,3, it is more important than ever to evaluate and improve primary and secondary outcomes as well as costs associated with these procedures. Tranexamic acid (TXA) has been widely used to improve morbidity and mortality in TKA, with substantial evidence demonstrating its efficacy in reducing blood loss6,7,11,12,13 and transfusion rates6,7,12. A meta-analysis done by Drain et al. also showed a significant reduction in periprosthetic joint infection (PJI) and length of stay4,12 in patients receiving any form of intraoperative TXA. Subsequent studies confirmed that TXA is safe for use in TKA, as it does not increase the incidence of complications including thromboembolic events and renal failure, even in high-risk populations5,6.

Recent literature has increasingly focused on comparing oral versus intravenous (IV) TXA in TKA, aiming to reduce costs while maintaining comparable safety and efficacy to the intravenous formulation. Current evidence strongly supports the noninferiority of preoperative oral TXA compared to IV TXA 8,9,10,14. Similar findings have been reported in revision TKA1. However, a key limitation of these studies is that their primary outcomes are often confined to blood loss, transfusion rates, thromboembolic events, and length of stay. Additionally, significant variability exists in the dosage regimens used across these studies.

While previous research has explored different formulations, doses, and delivery timings of TXA1,7,15, there is limited data on the optimal dosing strategy and length of administration for oral TXA. Most studies focus on perioperative administration, with few investigating the use of TXA beyond postoperative day one16,18,19. Some evidence supports extended IV TXA use for improving clinical parameters such as hemoglobin levels, though further research is needed18,19,20.

Currently, there is a lack of literature examining extended oral TXA use in primary TKA. Existing studies have produced conflicting results regarding pain and function outcomes16,21, with inconsistent dosing regimens further complicating efforts to draw firm conclusions.

Further evaluation of oral TXA administration during the perioperative period and beyond could provide valuable insights for enhancing the safety and reducing the costs of outpatient TKA. Establishing an optimal standard oral dose for prolonged TXA use could improve outcomes, support the transition to outpatient care, and provide consistent post-discharge management protocols.

The purpose of this study is to evaluate the efficacy and role of oral TXA in primary TKA by assessing pain, function, and range of motion over a 2-year follow-up period. We hypothesize that mid-term improvements in pain, function, and range of motion will be observed, with improved clinical outcomes such as arch of motion at the 2-year mark.

02

Conditions studied

  • Total Knee Arthroplasty

Browse trials for

Keywords

  • tranexamic acid
  • range of motion
  • postoperative pain
  • postoperative function
03

In context

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

This study's planned enrollment of 351 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Rush University Medical Center is the lead sponsor of 397 studies on the registry; 60 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient undergoing primary TKA at Rush main hospital or participating ASC
  • Willingness to undergo randomization to take medication potentially up to 7 days post op.
  • Willing to answer daily questions on pain, functionality and opioid consumption

Exclusion criteria

Exclusion Criteria:

  • History of venous thromboembolism, MI, or stroke in the past year
  • Patients on any chronic anticoagulation medications besides Aspirin
  • Patients with Cancer
  • Patients with end stage renal disease that are on dialysis
  • Drug allergy to TXA
  • Taking oral
  • Unable to provide consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
351 participants (estimated)

Study arms

  • Active comparator
    Oral-Short Arm: 1.95g TXA daily POD 1-3

    1.95g TXA daily for post operative days 1-3

    Drug: tranexamic acid Oral-Short Arm

  • Active comparator
    Oral-Long Arm

    1.95g TXA daily for post operative days 1-7

    Drug: tranexamic acid Oral-Long Arm

  • Placebo comparator
    Control Group: Placebo for 3 days post-op

    Placebo for 3 days post-op

    Drug: Control group placebo

Interventions

  • Drugtranexamic acid Oral-Short Arm

    1.95g Tranexamic acid daily for post op days 1 to 3

  • Drugtranexamic acid Oral-Long Arm

    1.95g tranexamic acid daily post op days 1-7

  • DrugControl group placebo

    Placebo for 3 days post-op

06

What researchers measure

Primary outcomes

  1. Primary endpoint: knee range of motion

    Primary Endpoint: Knee ROM

    Time frame: (flexion/extension) at 2 weeks and 6 weeks post op

Secondary outcomes

  1. Secondary" VAS pain scores

    Pain scores (VAS)

    Time frame: 2 weeks, 6 weeks, and 3 months post op

  2. Secondary: KOOS Jr

    Time frame: 2 weeks. 6 weeks, 3 months post op

  3. secondary: EQ-5D-3L functional scores

    Time frame: 2 weeks, 6 weeks, and 3 months post op

  4. Adverse events and complications

    Any adverse events or complications after surgery

    Time frame: 3 months post op

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — At the conclusion of the study, once all participants have completed all parts of the study

Supporting information: Study protocol, Statistical analysis plan

Time frame: 6 months following end of study and will last for a year

Access criteria: unending

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2027, 3 months later.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 3 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Sep 2026 → Dec 2026 and primary completion Dec 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 25, 2025
StartEst.
Dec 20, 2026was Sep 2026
Primary completionEst.
Apr 1, 2027was Dec 2026
CompletionEst.
May 1, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Dec 20, 2026
Oct 22, 2026
Primary completion
Dec 1, 2026→Apr 1, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Sep 1, 2026→Dec 20, 2026
    Primary completion Dec 1, 2026→Apr 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06894719
Responsible party
Bailey Terhune (Principle Investigator, Rush University Medical Center) — Principal investigator
First posted
Mar 25, 2025
Start date
Dec 20, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Anne DeBenedetti, MSc
Contact
anne.debenedetti@rushortho.com
13124322468
Marisa Toschi, BS
Contact
marisa.toschi@rushortho.com
312-432-2455
Bailey Terhune, MD
principal investigator · Rush University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion